Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Barclays upgrades IWG, says shares 'ripe for a re-rating'

(Sharecast News) - Barclays upgraded IWG on Friday to 'overweight' from 'equalweight' and hiked the price target to 260p from 161p as it said the shares are "ripe for a re-rating". It said that IWG - the largest operator of flex offices globally - is benefiting from a structural shift to hybrid working post the pandemic.

"However, the shares have been stagnant since the pandemic lockdowns were lifted and despite revenue, EBITDA and, most importantly, free cash flow exceeding pre-pandemic levels, the shares remain materially below pre-pandemic prices," it said.

"With investor confidence in management's ability to deliver having previously been shaken, we believe the market is still not giving IWG credit for its much-improved FCF generation, the capital-light expansion into Managed operations and management's recent tendency to under-promise and over-deliver."

Barclays said that in its view, after this period of caution/stagnation, the shares are ripe for a re-rating as we enter an inflection point, starting with the FY24 results on 4 March.

At 1035 GMT, the shares were up 3.7% at 182.80p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.